Johnson & Johnson cut 2026 profit forecast on Wednesday, citing the combined financial impact of its newly completed acquisition of Firefly Bio and a strategic partnership with Sail Biomedicines.
The healthcare giant expects full-year adjusted earnings per share of $10.96 to $11.11, compared with its previous forecast of $11.60 to $11.75
https://finance.yahoo.com/healthcare/articles/johnson-johnson-lowers-2026-profit-213823317.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.